Literature DB >> 22613675

Comparison of three different methods for the evaluation of IL28 and ITPA polymorphisms in patients infected with HCV.

Loretta Fiorina1, Stefania Paolucci, Stavros Papadimitriou, Fausto Baldanti.   

Abstract

A single nucleotide polymorphism (SNP) upstream of the IL28 gene (rs12979860) has been reported to predict sustained virological response to peginterferon-ribavirin therapy in chronic HCV patients. In addition, two functionally deficient variants (rs1127354 and rs7270101) of inosine triphosphatase (ITPA) were shown to protect against ribavirin (RBV) - induced hemolytic anemia during early stages of treatment. In this study, three methods for detecting IL28 and ITPA mutations were compared to evaluate accuracy, sensitivity costs and turn-around time. IL28 and ITPA variants were detected using genomic DNA from peripheral blood mononuclear cells (PBMCs) of 61 patients with chronic HCV infection by denaturing high-performance liquid chromatography (DHPLC), direct DNA sequencing analysis and Taq Man Real-Time SNP analysis. Complete concordance in the IL28 polymorphism analysis was observed among the three methods. As for ITPA polymorphisms, 60/61 (98.4%) samples were consistent among the three methods, while results for 1/61 (1.64%) samples were concordant by DHPLC and sequencing, and discordant by real-time SNP. All three methods are suitable for routine testing. On the other hand, screening by real-time SNP detection was less expensive and more rapid.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22613675     DOI: 10.1016/j.jviromet.2012.05.006

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  1 in total

1.  An index to predict ribavirin-induced anemia in asian patients with chronic genotype 1 hepatitis C.

Authors:  Sheng-Hung Chen; Cheng-Yuan Peng; Hsueh-Chou Lai; Wen-Pang Su; Chia-Hsin Lin; Yu-Fen Li; Po-Heng Chuang; Ching-Hsiang Chen
Journal:  Hepat Mon       Date:  2015-03-20       Impact factor: 0.660

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.